<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324207</url>
  </required_header>
  <id_info>
    <org_study_id>00006028</org_study_id>
    <secondary_id>00006028</secondary_id>
    <nct_id>NCT00324207</nct_id>
  </id_info>
  <brief_title>Molecular Quantification of Insulin mRNA</brief_title>
  <official_title>Prediction of Type 1 Diabetes: Molecular Quantification of Insulin mRNA in the While Cell Fraction of Whole Blood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Mercy Hospital Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Mercy Hospital Kansas City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to:&#xD;
&#xD;
        1. quantitate the level of insulin mRNA in the while cell fraction of whole blood in&#xD;
           selected groups of subjects,&#xD;
&#xD;
        2. determine the gene expression of markers of white cell activation in the white cell&#xD;
           fraction of whole blood in selected subjects,&#xD;
&#xD;
        3. determine the identity of the white cell responsible for expression of insulin mRNA and&#xD;
&#xD;
        4. determine protein expression of mRNA of insulin/proinsulin and selected genes of white&#xD;
           cell activation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indicators of active immune or chemically mediated beta cell destruction would be helpful for&#xD;
      predicting the development and severity of autoimmune diabetes and monitoring the success of&#xD;
      islet transplants. Currently there are no reliable indicators readily available.&#xD;
&#xD;
      Insulin mRNA in the white cell fraction of blood has been detected or elevated under several&#xD;
      circumstances including:&#xD;
&#xD;
        1. normal animals&#xD;
&#xD;
        2. after islet cell transplantation&#xD;
&#xD;
        3. hyperglycemic induced expression and&#xD;
&#xD;
        4. during induction of diabetes with streptozotocin&#xD;
&#xD;
      The investigators propose that quantitative measurement of insulin mRNA may be an accurate,&#xD;
      innovative and minimally invasive indicator of beta cell destruction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Hospital and clinic patients and their siblings.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects ages 1 to 17 years of age&#xD;
&#xD;
          2. Subjects with evidence of beta cell dysfunction or evidence of beta cell autoimmunity&#xD;
&#xD;
          3. Subjects with new onset type 1 diabetes&#xD;
&#xD;
          4. Non-diabetic and autoantibody negative siblings of subjects with new onset type 1&#xD;
             diabetes&#xD;
&#xD;
          5. Unrelated nondiabetic controls with no family history of type 1 diabetes&#xD;
&#xD;
          6. Of sufficient size to donate 10ml of blood&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None if subjects meet above inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne Moore, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Mercy Hospital Kansas City</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>May 8, 2006</study_first_submitted>
  <study_first_submitted_qc>May 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2006</study_first_posted>
  <last_update_submitted>March 3, 2010</last_update_submitted>
  <last_update_submitted_qc>March 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Wayne Moore, MD, PhD</name_title>
    <organization>The Children's Mercy Hospital</organization>
  </responsible_party>
  <keyword>Type 1 diabetes mellitus</keyword>
  <keyword>Insulin mRNA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

